Mark Erlander, Chief Scientific Officer at Trovagene, Inc. (TROV), bought 5,000 shares at $2.08 ($10K) on 2016-12-14, disclosed to the SEC on 2016-12-15.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| Filing → |
| CRDF | BUY | 2020-05-18 | $10K | — | Filing → |